Compare LU & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LU | ABUS |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.9M | 836.0M |
| IPO Year | 2020 | 2008 |
| Metric | LU | ABUS |
|---|---|---|
| Price | $7.17 | $4.16 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.54 | N/A |
| AVG Volume (30 Days) | 555.1K | ★ 2.2M |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 1.13 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | N/A | $1,208.75 |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | ★ N/A | $3.62 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $0.83 | $3.50 |
| 52 Week High | $9.60 | $5.45 |
| Indicator | LU | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 47.84 |
| Support Level | $1.38 | $3.59 |
| Resistance Level | $9.31 | $4.52 |
| Average True Range (ATR) | 0.61 | 0.20 |
| MACD | -0.30 | 0.03 |
| Stochastic Oscillator | 25.31 | 61.39 |
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.